{"id":59591,"date":"2026-03-16T14:27:53","date_gmt":"2026-03-16T06:27:53","guid":{"rendered":"https:\/\/flcube.com\/?p=59591"},"modified":"2026-03-16T14:27:54","modified_gmt":"2026-03-16T06:27:54","slug":"novartis-cosentyx-wins-fda-pediatric-approval-only-il-17a-inhibitor-for-hidradenitis-suppurativa-in-adolescents-12","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59591","title":{"rendered":"Novartis’ Cosentyx Wins FDA Pediatric Approval \u2013 Only IL-17A Inhibitor for Hidradenitis Suppurativa in Adolescents 12+"},"content":{"rendered":"\n

Novartis<\/strong> (NYSE:\u202fNVS<\/a>) announced that Cosentyx (secukinumab)<\/strong> received U.S. FDA approval<\/strong> for treating pediatric patients aged 12 years and older<\/strong> with moderate to severe hidradenitis suppurativa (HS)<\/strong>, making it the only IL-17A inhibitor approved for this population<\/strong>. The approval, supported by well-controlled adult studies<\/strong>, pharmacokinetic modeling<\/strong>, and pediatric data from other indications<\/strong>, enables weight-based dosing<\/strong> that provides similar exposure to adult HS patients<\/strong>. The expansion reinforces Cosentyx’s dominant IL-17A franchise<\/strong> across dermatology and rheumatology indications<\/strong> in both adult and pediatric populations<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>U.S. Food and Drug Administration (FDA)<\/td><\/tr>
Approval Type<\/strong><\/td>Pediatric indication expansion<\/td><\/tr>
Product<\/strong><\/td>Cosentyx (secukinumab)<\/td><\/tr>
Drug Class<\/strong><\/td>Fully human IL-17A inhibitor (biologic)<\/td><\/tr>
New Indication<\/strong><\/td>Moderate to severe hidradenitis suppurativa (HS) \u2013 pediatric patients \u226512 years<\/td><\/tr>
Weight Requirement<\/strong><\/td>\u226530 kg<\/td><\/tr>
Supportive Data<\/strong><\/td>Adult HS studies; PK modeling; pediatric data from other approved indications<\/td><\/tr>
Dosing Approach<\/strong><\/td>Weight-based dosing for similar exposure to adult HS patients<\/td><\/tr>
Competitive Position<\/strong><\/td>Only IL-17A inhibitor approved for pediatric HS<\/strong><\/td><\/tr>
Approval Date<\/strong><\/td>13\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Disease Context & Unmet Need<\/h2>\n\n\n\n
Parameter<\/th>Hidradenitis Suppurativa (HS)<\/th><\/tr><\/thead>
Disease Nature<\/strong><\/td>Chronic, systemic inflammatory skin disease<\/td><\/tr>
Clinical Features<\/strong><\/td>Recurring boil-like lesions; painful wounds; scarring; significant quality-of-life impact<\/td><\/tr>
Pediatric Burden<\/strong><\/td>Onset often in adolescence; previously limited targeted therapy options<\/td><\/tr>
Pathophysiology<\/strong><\/td>IL-17A-driven inflammation in hair follicles; Th17 immune response<\/td><\/tr>
Prior Pediatric Options<\/strong><\/td>Antibiotics, hormonal therapy, surgery; no biologics specifically approved for 12+ HS<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Cosentyx Approved Indications Portfolio<\/h2>\n\n\n\n
Population<\/th>Indications<\/th><\/tr><\/thead>
Adults<\/strong><\/td>HS, psoriatic arthritis (PsA), moderate-to-severe plaque psoriasis (PsO), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA)<\/td><\/tr>
Pediatrics (Current)<\/strong><\/td>HS (\u226512 years), PsO, enthesitis-related arthritis (ERA), juvenile psoriatic arthritis (JPsA)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

IL-17A Class Leadership:<\/strong><\/p>\n\n\n\n